Q-omics provides the consensus-scored CDC40 profile across patient tissues and cancer cell-line models. CDC40 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CDC40 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, CDC40 protein abundance shows 26,018 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where CDC40 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDC40 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDC40 survival associations across molecular data types. CDC40 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDC40 RNA expression–survival associations across cancer types. High CDC40 expression shows unfavorable associations in SCLC and LUSC, but favorable associations in KIRC, SKCM, UCS and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CDC40 RNA expression.
This table summarizes CDC40 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CDC40. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDC40 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, BLCA, STAD and CHOL. The HNSC box plot shows higher CDC40 RNA expression in tumor versus normal tissue (log2 FC = +0.626, t-test p < 0.001).
This table shows molecular features associated with CDC40 in patient tissues and cancer cell lines. In patient samples, CDC40 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CDC40 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and UPPER_AERODIGESTIVE_TRACT.
